small molecule

LAMOTRIGINE

Loss of exclusivity—loss of exclusivity

CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand name	LAMOTRIGINE
Active ingredient	LAMOTRIGINE
Strength	25MG
Dosage form	TABLET, ORALLY DISINTEGRATING
Route	ORAL
Modality	Small molecule
FDA approval	October 2025
Marketing status	RX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.